Finance

Lists
HDP1:FRA
Arrowhead Pharmaceuticals Inc
€72.40
+1.86%
(+1.32) 1D
Sep 11, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for HDP1...
Open
€71.06
High
€72.90
Low
€71.06
Mkt. cap
11.70B
Avg. vol.
4.00
Volume
0.00
52-wk high
€80.72
52-wk low
€23.47
No. of employees
711
Open
€71.06
High
€72.90
Low
€71.06
Mkt. cap
11.70B
Avg. vol.
4.00
Volume
0.00
52-wk high
€80.72
52-wk low
€23.47
No. of employees
711
Profile
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. Wikipedia
About Arrowhead Pharmaceuticals Inc
CEOChristopher Richard Anzalone
Employees711
FoundedJan 1, 2004
HeadquartersPasadena, California, United States
SectorBiotechnology
Websitearrowheadpharma.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
256.47M
264.03M
73.74M
75.25M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
181.07M
173.52M
165.66M
191.21M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
31.29M
49.70M
49.34M
54.14M
Operating expense
212.37M
223.22M
215.00M
245.35M
Total operating expenses
212.37M
223.22M
215.00M
245.35M
Operating income
44.11M
40.81M
-141.26M
-170.09M
Other non operating income
4.66M
277.00K
-1.61M
1.28M
EBT including unusual items
36.12M
28.27M
-137.56M
-178.90M
EBT excluding unusual items
36.12M
28.27M
-156.56M
-178.90M
Income tax expense
20.00M
29.00K
7.00K
11.00K
Effective tax rate
55.37%
0.10%
-0.01%
-0.01%
Other operating expenses
-
-
-
-
Net income
-23.75M
30.81M
-132.73M
-194.28M
Net profit margin
-9.26%
11.67%
-180.01%
-258.17%
Earnings per share
-0.18
0.22
-0.93
-1.36
Interest and investment income
9.05M
9.69M
16.87M
16.94M
Interest expense
-21.69M
-22.50M
-23.85M
-24.56M
Net interest expenses
-12.64M
-12.82M
-6.98M
-7.63M
Depreciation and amortization charges
-
-
-
-
EBITDA
50.49M
47.20M
-134.89M
-163.43M
Gain or loss from assets sale
-
-
-19.00M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps